Phase 2 N=20 Study of Tocilizumab to Treat Polymyalgia Rheumatica
Polymyalgia Rheumatica (PMR)
Primary: Proportion of Patients in Disease Remission at Six Months From Trial Entry — 9; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=11 Timed Release Tablet Prednisone in Polymyalgia Rheumatica
Polymyalgia Rheumatica
Primary: Change in Peak Serum IL-6 Concentration — 11.5; 29.3 pg/ml — p=<0.001
Phase 2 N=36 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Dermatomyositis · Polymyositis
Primary: Compare the Average Total Improvement Scores at Visits 2 Through 7 During the 6-month Treatment Period Between the Treatment and Placebo Arms — 26.4; 29.3 score on a…
Phase 3 N=31 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM
Polymyositis · Dermatomyositis
Primary: The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment. — 124; 135 mg/kg
Phase 2 N=30 Tocilizumab for Patients With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of Patients That Have Achieved Complete Remission of Disease — 17; 4 Participants — p=0.0301
Phase 2 N=200 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Myositis · Dermatomyositis · Polymyositis
Primary: Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients — 20.2; 20.0 Weeks — p==0.74
Phase 2 N=12 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Dermatomyositis · Polymyositis
Primary: Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI). — 7 Participants
Phase 2 N=25 A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Polymyositis · Dermatomyositis
Primary: Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period — 25.5; 25.0; 33.1; 33.5 score on a scale
Phase 4 N=30 Tocilizumab Plus a Short Prednisone Taper for GCA
Giant Cell Arteritis
Primary: Sustained Remission — 23 Participants
Phase 2 N=66 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
N/A N=1,002 The Maintaining Musculoskeletal Health Study
Widespread Chronic Pain
Primary: Development of Chronic Widespread Pain Assessed by Questionnaire — 69; 77 Participants
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
Phase 3 N=51 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Phase 2 N=83 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Takayasu's Arteritis · Giant Cell Arteritis
Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049
Phase 2 N=18 Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
Polymyositis · Dermatomyositis
Primary: Mean Total Improvement Score (TIS) at OLE Week 48 — 36.4 score on a scale
N/A N=377 Assessment of Giant Cell Arteritis Medical Practices in France
Giant Cell Arteritis
Primary: Patient Journey : Physicians Who Referred the Patient — 171; 31; 21; 17 Participants
Phase 4 N=147 Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)
Rheumatoid Arthritis
Primary: Change From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary — -16.76 minutes
Phase 2 N=15 Baricitinib in Relapsing Giant Cell Arteritis
Arteritis, Giant Cell
Primary: Adverse Events — 93 percentage of subjects
Phase 3 N=250 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
Giant Cell Arteritis
Primary: Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper) — 56.0; 53.1; 14.0…
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
Phase 3 N=197 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Vasculitis · Wegener's Granulomatosis · Microscopic Polyangiitis
Primary: Disease Remission — 63; 52 Participants — p=<0.001
Phase 2 N=323 Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8 — 47; 61; 69; 73 Percentage of participants
N/A N=356 Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey
Rheumatoid Arthritis
Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months
Phase 3 N=288 Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Relative Change From Baseline in Duration of Morning Stiffness at Week 12 — -22.7; -0.4 percent change
Phase 4 N=18 Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Pain Rating Index — -3.7 units on a scale
N/A N=165 Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants
Phase 2 N=75 A Study In Adults With Moderate To Severe Dermatomyositis
Dermatomyositis
Primary: Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) — -3.44…
Phase 2 N=70 KPL-301 for Subjects With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Time to Flare by Week 26 — NA; 25.1 weeks — p=0.0263
Phase 4 N=451 The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study
RheumatoId Arthritis
Primary: Signs and Symptoms: Mean DAS28 Post Baseline — 3.26; 3.62; 3.06; 3.42 score on a scale — p=<0.0001
N/A N=224 Effects of a Rheumatoid Arthritis Self-management Program
Arthritis, Rheumatoid
Primary: Disease Activity — 3.38; 3.62 score on a scale